Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy

J.P. van Wijk, A.I. Hoepelman, E. de Koning, G. Dallinga-Thie, T.J. Rabelink, M.C. Cabezas

Research output: Contribution to journal/periodicalArticleScientificpeer-review

Abstract

OBJECTIVE: To compare the effects of rosiglitazone (8 mg/d, n=19) and metformin (2 g/d, n=18) on postprandial lipemia in patients with HIV-lipodystrophy. METHODS AND RESULTS: Lipodystrophy in HIV is associated with insulin resistance and disturbed postprandial triglyceride and free fatty acid (FFA) metabolism. We conducted an open randomized 6-month study with standardized 10-h oral fat-loading tests at baseline and after treatment. Rosiglitazone (-34%) and metformin (-37%) reduced homeostasis model assessment similarly (P
Original languageEnglish
Pages (from-to)228-233
JournalArtheriosclerosis, Thrombosis and Vascular Biology
Volume31
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy'. Together they form a unique fingerprint.

Cite this